Tovorafenib
Tovorafenib is an oral, brain-penetrant, RAF kinase inhibitor that selectively inhibits BRAF monomers and dimers (including BRAF V600E mutations and certain non-V600E alterations) by functioning as a type II RAF inhibitor, blocking MAPK pathway-driven tumor cell proliferation. It is approved for pediatric patients with relapsed or refractory BRAF-altered pediatric low-grade glioma, and is under investigation for adult BRAF-altered cancers including colorectal and bladder cancers. Its once-weekly dosing and CNS penetration distinguish it from other RAF inhibitors.
Molekularmasse
506,3000 g/mol
LogP
3,00
TPSA
164,00 Ų
Lipinski-Regel der Fünf
Nicht bestanden
Therapeutische Bereiche
Wirkmechanismus
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
2D-Struktur
Cite this structure
Embed this structure
SMILES
C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
InChI
InChI=1S/C17H12Cl2F3N7O2S/c1-6(28-15(31)12-11(19)13(23)27-5-26-12)16-25-4-9(32-16)14(30)29-10-2-7(17(20,21)22)8(18)3-24-10/h2-6H,1H3,(H,28,31)(H2,23,26,27)(H,24,29,30)/t6-/m1/s1
Molecular Formula
C17H12Cl2F3N7O2S
HBD / HBA
3 / 11
Rotierbare Bindungen
5
Schwere Atome
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Tovorafenib is an oral, brain-penetrant, RAF kinase inhibitor that selectively inhibits BRAF monomers and dimers (including BRAF V600E mutations and certain non-V600E alterations) by functioning as a type II RAF inhibitor, blocking MAPK pathway-driven tumor cell proliferation. It is approved for pediatric patients with relapsed or refractory BRAF-altered pediatric low-grade glioma, and is under investigation for adult BRAF-altered cancers including colorectal and bladder cancers. Its once-weekly dosing and CNS penetration distinguish it from other RAF inhibitors.
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Yes, Tovorafenib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3348923. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25161177. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tovorafenib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tovorafenib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tovorafenib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tovorafenib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tovorafenib"></drugfyi-drug>